Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Analytical performance evaluation and enhancement of the ADVIA Centaur® HIV Ag/Ab Combo assay.

Demey B, Usureau C, Boillod P, Bodeau S, François C, Roussel C, Duverlie G, Castelain S, Brochot E.

J Clin Virol. 2019 Jul 25;118:36-40. doi: 10.1016/j.jcv.2019.07.007. [Epub ahead of print]

PMID:
31415958
2.

Synthesis and Study of New Quinolineaminoethanols as Anti-Bacterial Drugs.

Laumaillé P, Dassonville-Klimpt A, Peltier F, Mullié C, Andréjak C, Da-Nascimento S, Castelain S, Sonnet P.

Pharmaceuticals (Basel). 2019 Jun 18;12(2). pii: E91. doi: 10.3390/ph12020091.

3.

No correlation between Torque Teno virus viral load and BK virus replication after kidney transplantation.

Handala L, Descamps V, Morel V, Castelain S, François C, Duverlie G, Helle F, Brochot E.

J Clin Virol. 2019 Jul;116:4-6. doi: 10.1016/j.jcv.2019.03.018. Epub 2019 Apr 1.

PMID:
30986626
4.

Limited efficacy of nontreponemal test combined with treponemal test in the initial syphilis screening algorithm.

Gambiez C, Garet C, Choquet M, Decroix V, Pluquet E, Guiheneuf R, Castelain S.

J Med Microbiol. 2019 Feb;68(2):216-220. doi: 10.1099/jmm.0.000886. Epub 2018 Dec 20.

PMID:
30570479
5.

Characterization of a multidrug-resistant Klebsiella pneumoniae ST607-K25 clone responsible for a nosocomial outbreak in a neonatal intensive care unit.

Peltier F, Choquet M, Decroix V, Adjidé CC, Castelain S, Guiheneuf R, Pluquet E.

J Med Microbiol. 2019 Jan;68(1):67-76. doi: 10.1099/jmm.0.000884. Epub 2018 Dec 3.

PMID:
30507374
6.

Prospective evaluation of a screening algorithm for carbapenemase-producing Enterobacteriaceae.

Choquet M, Guiheneuf R, Castelain S, Pluquet E, Decroix V.

J Clin Lab Anal. 2019 Mar;33(3):e22706. doi: 10.1002/jcla.22706. Epub 2018 Nov 2.

PMID:
30390351
7.

Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review.

Demey B, Tinez C, François C, Helle F, Choukroun G, Duverlie G, Castelain S, Brochot E.

J Clin Virol. 2018 Dec;109:6-12. doi: 10.1016/j.jcv.2018.10.002. Epub 2018 Oct 12. Review.

PMID:
30343190
8.

Correction to: The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies.

Hoffmann TW, Delfosse F, Helle F, François C, Duverlie G, Castelain S.

Arch Virol. 2018 Dec;163(12):3485. doi: 10.1007/s00705-018-4044-y.

PMID:
30259143
9.

Multicenter performance evaluation of the Unyvero IAI cartridge for detection of intra-abdominal infections.

Ciesielczuk H, Wilks M, Castelain S, Choquet M, Morotti M, Pluquet E, Sambri V, Tassinari M, Zannoli S, Cavalié L, Dupont H, Guet-Revillet H.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2107-2115. doi: 10.1007/s10096-018-3345-0. Epub 2018 Aug 10.

PMID:
30094522
10.

BK polyomavirus in the urine for follow-up of kidney transplant recipients.

Brochot E, Descamps V, Handala L, Faucher J, Choukroun G, Helle F, Castelain S, François C, Duverlie G, Touzé A.

Clin Microbiol Infect. 2019 Jan;25(1):112.e1-112.e5. doi: 10.1016/j.cmi.2018.07.027. Epub 2018 Aug 1.

PMID:
30076973
11.

Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012-2016).

Fillatre A, François C, Segard C, Duverlie G, Hecquet D, Pannier C, Roussel C, Zawadzki P, Brochot E, Castelain S.

J Clin Virol. 2018 May;102:27-31. doi: 10.1016/j.jcv.2018.02.010. Epub 2018 Feb 20.

PMID:
29477833
12.

Comparison of Abbott Architect®, Siemens Immulite®, and Diasorin Liaison® for determination of Epstein-Barr virus serological diagnosis.

François C, Segard C, Bouvier M, Stefanski M, Pannier C, Zawadzki P, Roussel C, Hecquet D, Duverlie G, Brochot E, Castelain S.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):96-101. doi: 10.1016/j.diagmicrobio.2017.10.020. Epub 2017 Nov 7.

PMID:
29198371
13.

Biology of the BKPyV: An Update.

Helle F, Brochot E, Handala L, Martin E, Castelain S, Francois C, Duverlie G.

Viruses. 2017 Nov 3;9(11). pii: E327. doi: 10.3390/v9110327. Review.

14.

Comparison of MALDI-ToF MS with the Rapidec Carba NP test for the detection of carbapenemase-producing Enterobacteriaceae.

Choquet M, Guiheneuf R, Castelain S, Cattoir V, Auzou M, Pluquet E, Decroix V.

Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):149-155. doi: 10.1007/s10096-017-3115-4. Epub 2017 Oct 4.

PMID:
28980084
15.

Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus.

Fournier C, Hoffmann TW, Morel V, Descamps V, Dubuisson J, Brochot E, Francois C, Duverlie G, Castelain S, Helle F.

J Viral Hepat. 2018 Jan;25(1):63-71. doi: 10.1111/jvh.12767. Epub 2017 Aug 23.

PMID:
28772350
16.

High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients.

Castelain S, Descamps V, Brochot E, Helle F, Duverlie G, Nguyen-Khac E, François C.

Arch Virol. 2017 Jul;162(7):1913-1920. doi: 10.1007/s00705-017-3312-6. Epub 2017 Mar 13.

PMID:
28289975
17.

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles.

Oliveira C, Fournier C, Descamps V, Morel V, Scipione CA, Romagnuolo R, Koschinsky ML, Boullier A, Marcelo P, Domon JM, Brochot E, Duverlie G, Francois C, Castelain S, Helle F.

Hepatology. 2017 Jun;65(6):1851-1864. doi: 10.1002/hep.29096. Epub 2017 Apr 28.

18.

A Simple and Reliable Strategy for BK Virus Subtyping and Subgrouping.

Morel V, Martin E, François C, Helle F, Faucher J, Mourez T, Choukroun G, Duverlie G, Castelain S, Brochot E.

J Clin Microbiol. 2017 Apr;55(4):1177-1185. doi: 10.1128/JCM.01180-16. Epub 2017 Feb 1.

19.

Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity.

Ducancelle A, Pivert A, Bertrais S, Boursier J, Balan V, Veillon P, le Guillou-Guillemette H, Thibault V, Castelain S, Roquebert B, Coste-Burel M, Mackiewicz V, Schvoerer E, Larrat S, Maylin S, Alain S, Loustaud-Ratti V, Gordien E, Gozlan J, Brodard V, Chevaliez S, Calès P, Lunel-Fabiani F.

J Gastroenterol Hepatol. 2016 Oct;31(10):1750-1756. doi: 10.1111/jgh.13338.

PMID:
26992056
20.

The association between killer-cell immunoglobulin-like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation.

Brochot E, Desoutter J, Presne C, De Araujo I, Flahaut G, Castelain S, Westeel PF, Choukroun G, Guillaume N.

Transpl Int. 2016 Nov;29(11):1168-1175. doi: 10.1111/tri.12820. Epub 2016 Sep 12.

21.

Bartholinitis due to Aggregatibacter aphrophilus: a case report.

Choquet M, Pluquet E, Castelain S, Guihéneuf R, Decroix V.

BMC Infect Dis. 2016 Oct 18;16(1):574.

22.

Factors associated with delayed screening of contacts of tuberculosis cases in the Somme, France.

Yanogo PK, Schmit JL, Fresse AS, Andrejak C, Castelain S, Adjodah C, Ganry O.

Rev Epidemiol Sante Publique. 2016 Sep;64(4):247-53. doi: 10.1016/j.respe.2016.03.162. Epub 2016 Sep 2.

PMID:
27594695
23.

Place of diagnostic tools in the identification of Anaerobiospirillum succiniciproducens bacteraemia.

Decroix V, Pluquet E, Choquet M, Ammenouche N, Castelain S, Guiheneuf R.

Anaerobe. 2016 Jun;39:28-30. doi: 10.1016/j.anaerobe.2016.02.005. Epub 2016 Feb 16.

PMID:
26899447
24.

Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.

Izquierdo L, Oliveira C, Fournier C, Descamps V, Morel V, Dubuisson J, Brochot E, Francois C, Castelain S, Duverlie G, Helle F.

PLoS One. 2016 Feb 12;11(2):e0149064. doi: 10.1371/journal.pone.0149064. eCollection 2016.

25.

Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre.

Morel V, Ghoubra F, Izquierdo L, Martin E, Oliveira C, François C, Brochot E, Helle F, Duverlie G, Castelain S.

Infect Genet Evol. 2016 Jun;40:374-380. doi: 10.1016/j.meegid.2015.09.030. Epub 2015 Oct 9.

PMID:
26444584
26.

Comparative Evaluation of Three Nucleic Acid-Based Assays for BK Virus Quantification.

Descamps V, Martin E, Morel V, François C, Helle F, Duverlie G, Castelain S, Brochot E.

J Clin Microbiol. 2015 Dec;53(12):3822-7. doi: 10.1128/JCM.02116-15. Epub 2015 Sep 30.

27.

Factors associated with time to mandatory tuberculosis notification in the Somme department, France.

Yanogo PK, Schmit JL, Fresse AS, Andrejak C, Castelain S, Adjodah C, Ganry O.

Rev Epidemiol Sante Publique. 2015 Oct;63(5):299-303. doi: 10.1016/j.respe.2015.06.006. Epub 2015 Aug 31.

PMID:
26338701
28.

X4 Tropic Virus Prediction Is Associated with a Nadir CD4 T-Cell Count below 100 Cells/mm.

Sechet M, Roussel C, Schmit JL, Saroufim C, Ghomari K, Merrien D, Cordier F, Pik JJ, Landgraf N, Douadi Y, Liné D, Duverlie G, Castelain S.

Intervirology. 2015;58(3):155-9. doi: 10.1159/000398798. Epub 2015 May 21.

29.

The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.

Descamps V, Helle F, Louandre C, Martin E, Brochot E, Izquierdo L, Fournier C, Hoffmann TW, Castelain S, Duverlie G, Galmiche A, François C.

Antiviral Res. 2015 Jun;118:93-102. doi: 10.1016/j.antiviral.2015.03.012. Epub 2015 Mar 28.

PMID:
25823619
30.

Which therapeutic option for hepatitis C virus genotype 1?

Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G.

Scand J Gastroenterol. 2015 Apr;50(4):470-8. doi: 10.3109/00365521.2014.978364. Epub 2014 Nov 14. Review.

PMID:
25396710
31.

Alginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infections.

Tran NM, Dufresne M, Helle F, Hoffmann TW, François C, Brochot E, Paullier P, Legallais C, Duverlie G, Castelain S.

PLoS One. 2014 Oct 13;9(10):e109969. doi: 10.1371/journal.pone.0109969. eCollection 2014.

32.

Simeprevir for the treatment of hepatitis C virus infection.

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E.

Pharmgenomics Pers Med. 2014 Aug 14;7:241-9. doi: 10.2147/PGPM.S52715. eCollection 2014. Review.

33.

The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies.

Hoffmann TW, Delfosse F, Helle F, François C, Duverlie G, Castelain S.

Arch Virol. 2014 Mar;159(3):527-34. doi: 10.1007/s00705-013-1862-9. Epub 2013 Oct 8. Erratum in: Arch Virol. 2018 Dec;163(12):3485.

PMID:
24100473
34.

The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse.

Bodeau S, Durand-Maugard C, Lemaire-Hurtel AS, François C, Castelain S, Helle F, Andréjak M, Nguyen-Khac E, Duverlie G, Brochot E.

Ther Drug Monit. 2013 Dec;35(6):791-5. doi: 10.1097/FTD.0b013e3182966dee.

PMID:
23942546
35.

Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.

Helle F, Brochot E, Fournier C, Descamps V, Izquierdo L, Hoffmann TW, Morel V, Herpe YE, Bengrine A, Belouzard S, Wychowski C, Dubuisson J, Francois C, Regimbeau JM, Castelain S, Duverlie G.

PLoS One. 2013 Aug 5;8(8):e70809. doi: 10.1371/journal.pone.0070809. Print 2013.

36.

Are trans-complementation systems suitable for hepatitis C virus life cycle studies?

Fournier C, Duverlie G, Castelain S.

J Viral Hepat. 2013 Apr;20(4):225-33. doi: 10.1111/jvh.12069. Epub 2013 Feb 14. Review.

PMID:
23490366
37.

Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes.

Fournier C, Helle F, Descamps V, Morel V, François C, Dedeurwaerder S, Wychowski C, Duverlie G, Castelain S.

J Gen Virol. 2013 May;94(Pt 5):996-1008. doi: 10.1099/vir.0.049676-0. Epub 2013 Jan 3.

PMID:
23288424
38.

A new tool to study ribavirin-induced haemolysis.

Brochot E, François C, Castelain S, Helle F, Van Nhien AN, Duchaussoy I, Capron D, Nguyen-Khac E, Duverlie G.

Antivir Ther. 2012;17(7):1311-7. doi: 10.3851/IMP2308. Epub 2012 Sep 5.

PMID:
22951364
39.

An appropriate selection of a 3D alginate culture model for hepatic Huh-7 cell line encapsulation intended for viral studies.

Tran NM, Dufresne M, Duverlie G, Castelain S, Défarge C, Paullier P, Legallais C.

Tissue Eng Part A. 2013 Jan;19(1-2):103-13. doi: 10.1089/ten.TEA.2012.0139. Epub 2012 Oct 1.

PMID:
22889091
40.

Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients.

Descamps V, Op de Beeck A, Plassart C, Brochot E, François C, Helle F, Adler M, Bourgeois N, Degré D, Duverlie G, Castelain S.

J Clin Microbiol. 2012 Feb;50(2):465-8. doi: 10.1128/JCM.06503-11. Epub 2011 Dec 7.

41.

The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.

François C, Coulouarn C, Descamps V, Castelain S, Brochot E, Baron A, Duchaussoy I, Capron D, Nguyen-Khac E, Duverlie G.

Antimicrob Agents Chemother. 2012 Feb;56(2):903-8. doi: 10.1128/AAC.05646-11. Epub 2011 Nov 28.

42.

Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.

Moura M, Josse S, Nguyen Van Nhien A, Fournier C, Duverlie G, Castelain S, Soriano E, Marco-Contelles J, Balzarini J, Postel D.

Eur J Med Chem. 2011 Oct;46(10):5046-56. doi: 10.1016/j.ejmech.2011.08.017. Epub 2011 Aug 22.

PMID:
21880398
43.

Genetic recombination of the hepatitis C virus: clinical implications.

Morel V, Fournier C, François C, Brochot E, Helle F, Duverlie G, Castelain S.

J Viral Hepat. 2011 Feb;18(2):77-83. doi: 10.1111/j.1365-2893.2010.01367.x. Epub 2010 Sep 6. Review.

PMID:
21235686
44.

Molecular characterization of glycopeptide-resistant enterococci from hospitals of the picardy region (france).

Biendo M, Adjidé C, Castelain S, Belmekki M, Rousseau F, Slama M, Ganry O, Schmit JL, Eb F.

Int J Microbiol. 2010;2010:150464. doi: 10.1155/2010/150464. Epub 2010 Oct 31.

45.

Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.

Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J.

J Virol. 2010 Nov;84(22):11905-15. doi: 10.1128/JVI.01548-10. Epub 2010 Sep 15.

46.

Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.

François C, Descamps V, Brochot E, Bernard I, Canva V, Mathurin P, Castelain S, Duverlie G.

J Med Virol. 2010 Oct;82(10):1640-6. doi: 10.1002/jmv.21837.

PMID:
20827759
47.

Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.

Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, François C.

Antivir Ther. 2010;15(5):687-95. doi: 10.3851/IMP1609. Review.

PMID:
20710050
48.

Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report.

Morel V, Descamps V, François C, Fournier C, Brochot E, Capron D, Duverlie G, Castelain S.

J Clin Virol. 2010 Apr;47(4):382-6. doi: 10.1016/j.jcv.2010.01.011. Epub 2010 Feb 13.

PMID:
20153975
49.

Optimizing the treatment of chronic viral hepatitis C.

François C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E.

Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):607-13. doi: 10.1586/egh.09.60. Review.

PMID:
19929582
50.

Enhanced anti-HCV activity of interferon alpha 17 subtype.

Dubois A, François C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G.

Virol J. 2009 Jun 3;6:70. doi: 10.1186/1743-422X-6-70.

Supplemental Content

Loading ...
Support Center